.mw-parser-output .noboldfont-weight:normal NY (what is this?) (verify)
Glimepiride, sold under the trade name Amaryl among others, is medium-to-long-acting sulfonylurea antidiabetic medication. It is taken by mouth. It is sometimes classified as either the first third-generation sulfonylurea,[1] or as second-generation.[2]
In 2016 it was the 61st most prescribed medication in the United States with more than 12 million prescriptions.[3]
Contents
1Medical uses
2Contraindications
3Adverse effects
4Interactions
5Pharmacokinetics
6Mechanism of action
7References
8External links
Medical uses[edit]
Main article: Sulfonylurea
Glimepiride is indicated to treat type 2 diabetes mellitus; its mode of action is to increase insulin secretion by the pancreas. However it requires adequate insulin synthesis as prerequisite to treat appropriately. It is not used for type 1 diabetes because in type 1 diabetes the pancreas is not able to produce insulin.[4]
Contraindications[edit]
Its use is contraindicated in patients with hypersensitivity to glimepiride or other sulfonylureas.
Adverse effects[edit]
Side effects from taking glimepiride include gastrointestinal tract (GI) disturbances, occasional allergic reactions, and rarely blood production disorders including thrombocytopenia, leukopenia, and hemolytic anemia. In the initial weeks of treatment, the risk of hypoglycemia may be increased. Alcohol consumption and exposure to sunlight should be restricted because they can worsen side effects.[4]
Interactions[edit]
Nonsteroidal anti-inflammatory drugs (such as salicylates), sulfonamides, chloramphenicol, coumadin and probenecid may potentiate the hypoglycemic action of glimepiride. Thiazides, other diuretics, phothiazides, thyroid products, oral contraceptives, and phenytoin tend to produce hyperglycemia.
Pharmacokinetics[edit]
Two generic oral tablets of glimepiride, 2 mg each
Gastrointestinal absorption is complete, with no interference from meals. Significant absorption can occur within one hour, and distribution is throughout the body, 99.5% bound to plasma protein. Metabolism is by oxidative biotransformation, it is hepatic and complete. First, the medication is metabolized to M1 metabolite by CYP2C9. M1 possesses about 1⁄3 of pharmacological activity of glimepiride, yet it is unknown if this results in clinically meaningful effect on blood glucose. M1 is further metabolized to M2 metabolite by cytosolic enzymes. M2 is pharmacologically inactive. Excretion in the urine is about 65%, and the remainder is excreted in the feces.
Mechanism of action[edit]
Main article: Sulfonylurea
Like all sulfonylureas, glimepiride acts as an insulin secretagogue.[5] It lowers blood sugar by stimulating the release of insulin by pancreatic beta cells and by inducing increased activity of intracellular insulin receptors.
Not all secondary sufonylureas have the same risk of hypoglycemia. Glibenclamide (glyburide) is associated with an incidence of hypoglycemia of up to 20–30%, compared to as low as 2% to 4% with glimepiride. Glibenclamide also interferes with the normal homeostatic suppression of insulin secretion in reaction to hypoglycemia, whereas glimepiride does not. Also, glibenclamide diminishes glucagon secretion in reaction to hypoglycemia, whereas glimepiride does not.[6]
^Davis SN (2004). "The role of glimepiride in the effective management of Type 2 diabetes". J. Diabetes Complicat. 18 (6): 367–76. doi:10.1016/j.jdiacomp.2004.07.001. PMID 15531188.
^"The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.
^ ab"Glimepiride: MedlinePlus Drug Information". nih.gov.
^Nissen SE, Nicholls SJ, Wolski K, et al. (April 2008). "Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial". JAMA. 299 (13): 1561–73. doi:10.1001/jama.299.13.1561. PMID 18378631.
^Davis, Stephen N. (2005). "60. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas". In Brunton, Laurence L.; Lazo, John S.; Parker, Keith L. (eds.). Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill. p. 1636. ISBN 0-07-142280-3.CS1 maint: Uses editors parameter (link)
The Dalles, Oregon From Wikipedia, the free encyclopedia Jump to navigation Jump to search This article is about the city in Oregon. For the nearby geological formation, see Celilo Falls. For other uses, see Dalles. Not to be confused with the town of Dallas, Oregon. City in Wasco County The Dalles City The Dalles and the Columbia River in November 2008 Flag Seal Motto(s): "Cognito timor Vincit" (Latin), "Knowledge Conquers Fear" (English) Location in Oregon Coordinates: 45°36′4″N 121°10′58″W / 45.60111°N 121.18278°W / 45.60111; -121.18278 Coordinates: 45°36′4″N 121°10′58″W / 45.60111°N 121.18278°W / 45.60111; -121.18278 County Wasco County Incorporated 1857 Government • Mayor Stephen Elliott Lawrence (D) [1] [2] Area [3] • Total 6.61 sq mi (17.12...